NCT02693535 2026-02-13
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
Clinical Trials
7 trialsNCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT06263153 2025-12-17
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT04828486 2025-11-18
Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer
Mayo Clinic
Phase 2 Completed
NCT05036681 2025-09-17
A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05615818 2025-04-23
SAFIR-ABC10
UNICANCER
Phase 3 Recruiting
NCT03767075 2024-04-25
BoB
Vall d'Hebron Institute of Oncology
Phase 2 Recruiting